MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, responded to investor inquiries in connection with the significant increase in trading and volatility of its common stock over the past few days. The Company knows of no development associated with its clinical activities that would explain the decline in the price of its common stock. In fact, the clinical activities continue to exceed the Company’s expectations and are on schedule.
